Group 1 - Dr. Debra Yu will be appointed as a new member of the Board Nomination Committee, effective from December 26, 2025 [1] - Dr. David Sidransky will be appointed as the Chief Independent Non-Executive Director, effective from December 26, 2025, to act as an intermediary between other directors and the company's shareholders, and to communicate with other directors and shareholders when normal communication channels with the Board Chairman or management are insufficient [1] - A Research and Development Committee will be established, effective from December 26, 2025, composed of scientists, doctors, and business experts to oversee R&D strategies, product lines, investments, and emerging trends while managing risks and ensuring alignment with business objectives [1] Group 2 - The R&D Committee will be chaired by Dr. Marc E. Lippman, with Dr. David Sidransky and Dr. Wang Shaomeng as members [1]
亚盛医药-B：David Sidransky将获委任为首席独立非执行董事